EUVIMEDEUVIMED entdecken
Crossref

Integration of Metabolic Profiling and Functional Genomics Suggests IGJ as a Driver of Chemoresistance in B‐ALL

Karen Lizeth Pachón-Meza iD, Camilo Ernesto Moreno-Cristancho iD, José Luis Padilla-Agudelo iD, Ana Isabel Ramos-Murillo iD, Diana Londoño-Barbosa iD, Gustavo Salguero iD, Sandra Milena Sanabria-Barrera iD, Claudia Chica iD, Nataly Cruz-Rodriguez iD, Rubén Darío Godoy-Silva iD, José Arturo Gutiérrez-Triana iD

Pediatric Blood & Cancer · 2025

DOI: 10.1002/pbc.32068 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Karen Lizeth Pachón-Meza und 10 weiteren Autor:innen. Beteiligte Einrichtung: Immunology and Molecular Epidemiology Research Group (GIEM), Escuela de Microbiologia, Facultad De Salud, Universidad Industrial de Santander, Bucara…. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Genomics, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Ministerio de Ciencia, Tecnología e Innovación.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

B‐cell precursor acute lymphoblastic leukemia (B‐ALL) is a hematologic malignancy characterized by the uncontrolled proliferation of immature B lymphoblasts. Despite significant advancements in treatment, chemoresistance remains a major challenge. Previous studies, including those involving Colombian patient cohorts, have identified a gene signature involving ID1, ID3 , and IGJ , which correlates with poor prognosis; however, the underlying mechanisms remain unclear. This study integrates metabolic profiling with gene expression analysis of ID1, ID3 , and IGJ in patient‐derived lymphoblasts. It explores the role of IGJ overexpression in NALM‐6 cells to assess its potential contribution to chemoresistance.

Methods

Bone marrow samples from 33 newly diagnosed B‐ALL patients were analyzed for ID1, ID3 , and IGJ gene expression. Seahorse XF metabolic assays were conducted on 13 patient samples to assess mitochondrial respiration and glycolytic function. Functional studies were performed in the NALM‐6 B‐ALL cell line using CRISPRa‐mediated IGJ overexpression, followed by metabolic and chemoresistance assays using resazurin‐based viability testing with key chemotherapeutic agents.

Results

Patient‐derived lymphoblasts exhibited a quiescent metabolic phenotype, with two distinct metabolic subgroups based on oxygen consumption and glycolysis rates. Higher IGJ expression was significantly associated with the glycolytic subgroup and correlated with worse event‐free survival (EFS, p = 0.0179) and overall survival (OS, p = 0.0205). In NALM‐6 cells, IGJ overexpression led to increased metabolic activity and conferred resistance to dexamethasone, cytarabine, doxorubicin, and methotrexate, but not cyclophosphamide.

Conclusion

IGJ upregulation promotes metabolic reprogramming and chemoresistance in B‐ALL, suggesting a potential role for IGJ as a biomarker and therapeutic target in overcoming treatment resistance. These findings provide new insights into the metabolic mechanisms underlying B‐ALL progression and highlight IGJ as a candidate for future targeted interventions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, NeoplasmPrecursor B-Cell Lymphoblastic Leukemia-LymphomaGenomicsBiomarkers, TumorMetabolomicsHumansMaleFemaleChildChild, PreschoolAdolescentPrognosisTumor Cells, Cultured

Stichwörter der Autor:innen

B‐cell precursor acute lymphoblastic leukemiaCRISPRadrug resistancemetabolismmitochondrial respiration

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Immunology and Molecular Epidemiology Research Group (GIEM), Escuela de Microbiologia, Facultad De Salud, Universidad Industrial de Santander, Bucaramanga, Colombia.
  • Research Group on Chemical and Biochemical Processes, Departamento De Ingenieria Quimica y Ambiental, Universidad Nacional de Colombia, Bogota, Colombia.
  • Departamento De Investigación y Desarrollo, BIOARTIFICIAL BIC, Clichy, France.
  • Advanced Therapy Unit, Instituto Distrital de Ciencia, Biotecnologia e Innovacion en Salud (IDCBIS), Bogota, Colombia.
  • Fundación Cardiovascular de Colombia, Laboratorio De Investigaciones, Colombia.
  • Institut Pasteur, Université Paris Cité, Paris, France.

ORCID-Profile: Karen Lizeth Pachón-Meza, Camilo Ernesto Moreno-Cristancho, José Luis Padilla-Agudelo, Ana Isabel Ramos-Murillo, Diana Londoño-Barbosa, Gustavo Salguero, Sandra Milena Sanabria-Barrera, Claudia Chica, Nataly Cruz-Rodriguez, Rubén Darío Godoy-Silva, José Arturo Gutiérrez-Triana

Förderung

  • Ministerio de Ciencia, Tecnología e Innovación

Zitieren

APA

Pachón-Meza, K. L., Moreno-Cristancho, C. E., Padilla-Agudelo, J. L., Ramos-Murillo, A. I., Londoño-Barbosa, D., Salguero, G., Sanabria-Barrera, S. M., Chica, C., Cruz-Rodriguez, N., Godoy-Silva, R. D., & Gutiérrez-Triana, J. A. (2025). Integration of Metabolic Profiling and Functional Genomics Suggests IGJ as a Driver of Chemoresistance in B‐ALL. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.32068

Vancouver

Pachón-Meza KL, Moreno-Cristancho CE, Padilla-Agudelo JL, Ramos-Murillo AI, Londoño-Barbosa D, Salguero G, et al. Integration of Metabolic Profiling and Functional Genomics Suggests IGJ as a Driver of Chemoresistance in B‐ALL. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.32068

BibTeX
@article{PachnMeza2025,
  author = {Pachón-Meza, Karen Lizeth and Moreno-Cristancho, Camilo Ernesto and Padilla-Agudelo, José Luis and Ramos-Murillo, Ana Isabel and Londoño-Barbosa, Diana and Salguero, Gustavo and Sanabria-Barrera, Sandra Milena and Chica, Claudia and Cruz-Rodriguez, Nataly and Godoy-Silva, Rubén Darío and Gutiérrez-Triana, José Arturo},
  title = {Integration of Metabolic Profiling and Functional Genomics Suggests IGJ as a Driver of Chemoresistance in B‐ALL},
  journal = {Pediatric Blood & Cancer},
  year = {2025},
  doi = {10.1002/pbc.32068}
}
Kostenlos starten →